Upgrade to SI Premium - Free Trial

Veeva Systems (VEEV) Tops Q3 EPS by 10c, Revenues Beat; Offers 4Q & FY21 EPS/Revenue Guidance Above Consensus, FY22 Revenue Outlook Above Consensus

December 1, 2020 4:13 PM

Veeva Systems (NYSE: VEEV) reported Q3 EPS of $0.78, $0.10 better than the analyst estimate of $0.68. Revenue for the quarter came in at $377.5 million versus the consensus estimate of $361.82 million.

Fiscal 2021 Third Quarter Results:

“Our customers are delivering innovations that will have positive, lasting impacts on human health,” said CEO Peter Gassner. “We are proud to work with these amazing companies, providing solutions that streamline drug development and enable them to support healthcare providers on the front lines.”

“I am very pleased with our financial outperformance in the quarter, which was a direct result of our strong vision and focused execution,” said CFO Brent Bowman. “As we look to the opportunities ahead, we plan to continue investing aggressively to hit our 2025 targets and drive a long runway of growth beyond.”

GUIDANCE:

Veeva Systems sees Q4 2021 EPS of $0.67-$0.68, versus the consensus of $0.62. Veeva Systems sees Q4 2021 revenue of $378-380 million, versus the consensus of $367.64 million.

Veeva Systems sees FY2021 EPS of $2.83-$2.84, versus the consensus of $2.68. Veeva Systems sees FY2021 revenue of $1.446-1.448 billion, versus the consensus of $1.42 billion.

Veeva Systems sees FY2022 revenue of $1.7-1.72 billion, versus the consensus of $1.7 billion.

Veeva is providing guidance for its fiscal fourth quarter ending January 31, 2021 as follows:

Veeva is providing guidance for its fiscal year ending January 31, 2021 as follows:

Veeva is providing guidance for its fiscal year ending January 31, 2022 as follows:

For earnings history and earnings-related data on Veeva Systems (VEEV) click here.

Categories

Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles